New drug trial targets tough blood cancers in japan
NCT ID NCT03198650
Summary
This early-stage study is testing a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers, such as certain types of leukemia and lymphoma. The main goal is to check the drug's safety, how the body processes it, and see if it shows any signs of fighting the cancer. The study is divided into parts to test different doses and combinations in patients whose cancer has come back or hasn't responded to prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PART1: ADVANCED B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Chiba, 260-8717, Japan
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Fukuoka, 812-8582, Japan
-
Research Site
Isehara-shi, 259-1193, Japan
-
Research Site
Izumo-shi, 693-8501, Japan
-
Research Site
Matsuyama, 791-0280, Japan
-
Research Site
Nagoya, 460-0001, Japan
-
Research Site
Nagoya, 464-8681, Japan
-
Research Site
Niigata, 951-8520, Japan
-
Research Site
Okayama, 700-8558, Japan
-
Research Site
Sapporo, 060-8638, Japan
-
Research Site
Sendai, 980-8574, Japan
-
Research Site
Shimotsuke-shi, 329-0498, Japan
-
Research Site
Suita-shi, 565-0871, Japan
Conditions
Explore the condition pages connected to this study.